Skip to main navigation

Ocular Therapeutix Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD Read More

Investors
Patients
Careers
- Benefits
- Open Positions
Contact Us

Search

About
Retinal Disease
Technology
Pipeline
Products

Search

Investors

Overview
Press
Releases
Events &
Presentations
Scientific &
Medical Presentations
SEC
Filings
Corporate
Governance
Stock
Information
FAQs
Email
Alerts

Event Details

Baird 2026 Global Healthcare Conference

September 15, 2026 at 10:50 AM EDT

Supporting Materials

Webcast Replay 43.8 MB

About
Company Overview
Management Team
Board of Directors
Global Scientifc
Advisory Board

Investors
Press Releases
Events & Presentations
Scientific & Medical Presentations
SEC Filings
Corporate Governance
Stock Information
FAQs
Email Alerts

Retinal Disease
Technology
Pipeline
Products

© Ocular Therapeutix, Inc. All rights reserved. DEXTENZA is a registered trademark and ELUTYX, AXPAXLI, RETINA EXPERIENCE REDEFINED, OCULAR THERAPEUTIX, and OCULAR THERAPEUTIX Logo are trademarks of Ocular Therapeutix, Inc.

Terms of Use
Privacy Policy
Compliance
Expanded Access Program